Increased CSF biomarkers of angiogenesis in Parkinson disease
Open Access
- 23 November 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 85 (21), 1834-1842
- https://doi.org/10.1212/WNL.0000000000002151
Abstract
Objective:To study biomarkers of angiogenesis in Parkinson disease (PD), and how these are associated with clinical characteristics, blood-brain barrier (BBB) permeability, and cerebrovascular disease.Methods:In this cross-sectional analysis, 38 elderly controls and 100 patients with PD (82 without dementia and 18 with dementia) were included from the prospective Swedish BioFinder study. CSF samples were analyzed for the angiogenesis biomarkers vascular endothelial growth factor (VEGF); its receptors, VEGFR-1 and VEGFR-2; placental growth factor (PlGF); angiopoietin 2 (Ang2); and interleukin-8. BBB permeability, white matter lesions (WMLs), and cerebral microbleeds (CMB) were assessed. CSF angiogenesis biomarkers were also measured in 2 validation cohorts: (1) 64 controls and 87 patients with PD with dementia; and (2) 35 controls and 93 patients with neuropathologically confirmed diagnosis of PD with and without dementia.Results:Patients with PD without dementia displayed higher CSF levels of VEGF, PlGF, and sVEGFR-2, and lower levels of Ang2, compared to controls. Similar alterations in VEGF, PlGF, and Ang2 levels were observed in patients with PD with dementia. Angiogenesis markers were associated with gait difficulties and orthostatic hypotension as well as with more pronounced BBB permeability, WMLs, and CMB. Moreover, higher levels of VEGF and PlGF levels were associated with increased CSF levels of neurofilament light (a marker of neurodegeneration) and monocyte chemotactic protein-1 (a marker of glial activation). The main results were validated in the 2 additional cohorts.Conclusions:CSF biomarkers of angiogenesis are increased in PD, and they are associated with gait difficulties, BBB dysfunction, WMLs, and CMB. Abnormal angiogenesis may be important in PD pathogenesis and contribute to dopa-resistant symptoms.This publication has 40 references indexed in Scilit:
- Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairmentBrain, Behavior, and Immunity, 2013
- Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samplesAlzheimer's Research & Therapy, 2013
- Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s diseaseJournal of Neuroinflammation, 2012
- Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory diseaseJCI Insight, 2012
- CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's DiseasePLOS ONE, 2012
- Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesiaBrain, 2011
- Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsyJournal of Neural Transmission, 2011
- Corneal avascularity is due to soluble VEGF receptor-1Nature, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences of the United States of America, 1993